Loading... Please wait...
App Store Download on the App Store Google Play GET IT ON Google Play

Otonomy, Inc. (OTIC) Stock Price, News & Analysis

Currency in USD Disclaimer
$0.01
$0.02
$0.01
$2.51
Notice: This company has been marked as potentially delisted and may not be actively trading.
Track all markets on TradingView

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -17.01
  • Piotroski Score 2.00
  • Grade N/A

Company brief: Otonomy, Inc. (OTIC)

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Company Calendar

  • N/A
  • 04/11/2023
  • N/A
  • N/A
  • 07/24/2023
  • N/A

Price Target and Rating

  • $6.00
  • $6.00
  • $6.00
  • N/A
  • Neutral
  • N/A
  • N/A

Profitability

  • -$0.06
  • -0.14166666666667
  • -0.14166666666667
  • -0.14166666666667
  • $-50,325,000

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Latest News of OTIC

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In

or
Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Sign Up With Email Address
or
Continue with Google Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.